Estimating the cost of health care-assodated infections: Mind your p's and q's

Clinical Infectious Diseases

Volumn 50, Issue 7, 2010, Pages 1017-1021

  Graves, Nicholas ^a,b   Harbarth, Stephan ^c   Beyersmann, Jan ^d,e   Barnett, Adrian ^a   Halton, Kate ^a,b   Cooper, Ben ^f  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b Centre for Healthcare Related Infection Surveillance and Prevention (CRISP)   (Australia)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; FUNDING; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; INFECTION; INFECTION CONTROL; INFORMATION; LENGTH OF STAY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

COSTS AND COST ANALYSIS; CROSS INFECTION; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC;

EID: 77749334885     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651110     Document Type: Review

References (54)

1. Layard RN, Glaister S. Introduction. In: Layard R, Glaister S, eds. Costbenefit analysis. 4ťh ed. London, UK: Cambridge Publishing, 1994:1-56.
2. Cohen DR. Economic issues in infection control. J Hosp Infect 1984; 5(suppl A):17-25.
3. Graves N, Haiton K, Lairson D. Economics and preventing hospitalacquired infection-broadening the perspective. Infect Control Hosp Epidemiol 2007;28:178-184. (Pubitemid 46374158)
4. Drummond MR Davies LE Evaluation of the costs and benefits of reducing hospital infection. J Hosp Infect 1991;18(suppl 18):85-93.
5. Graves N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561-566.
6. Graves N, Halton K, Jarvis WR. Economics and preventing healthcare acquired infection. New York, NY: Springer Science+Business Media, 2009.
7. Harbarth S, Sax H, Gastmeier R The preventable proportion of nosocomial infections: an overview of published reports. J Hosp Infect 2003; 54:258-266. (Pubitemid 37554920)
8. Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control 2005;33:501-509. (Pubitemid 41551611)
9. Stone PW, Larson E, Kawar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control 2002;30:145-152.
10. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, UK: Oxford University Press, 2005.
11. Graves N, McGowan JE. Nosocomial infection, the deficit reduction act and incentives for hospitals. JAMA 2008;300:1577-1579.
12. Perencevich EN, Stone PW, Wright SB, et al. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol 2007;28:1121-1133.
13. Bhavnani SM, Prakhya A, Hammel JP, et al. Cost-effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis. Clin Infect Dis 2009;49:691-698.
14. Elliott RA, Weatherly HL, Hawkins NS, et al. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? Eur J Health Econ doi:10.1007/ S10198-009-0175-180 Published 8 August 2009.
15. Halton KA, Cook DA, Whitby M, et al. Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. Crit Care 2009;13:R35.
16. Schulz MC, Nonnenmacher C, Mutters R. Cost-effectiveness of rapid MRSA screening in surgical patients. Eur J Clin Microbiol Infect Dis 2009;28:1291-1296.
17. Halton K, Graves N. Economics of preventing catheter-related bloodstream infection? Emerg Infect Dis 2007;13:815-823.
18. Barnett AG, Batra R, Graves N, et al. Using a longitudinal model to estimate the effect of methicillin-resistant Staphylococcus aureus infection on length of stay in an intensive care unit. Am J Epidemiol 2009; 170:1186-1194.
19. Samore M, Harbarth S. A methodologically focused review of the literature in hospital epidemiology and infection control (chapter 93). In: Mayhall CG. Hospital epidemiology and infection control. 3rd edition. Philadelphia, PA: Lippincott Williams 8: Wilkins, 2004.
20. Schulgen G, Schumacher M. Estimation of prolongation of hospital stay attributable to nosocomial infections. Lifetime Data Anal 1996;2: 219-240.
21. Beyersmann J, Gastmeier P, Wolkewitz M, et al. An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol 2008;61:1216-1221.
22. Beyersmann J, Kneib T, Schumacher M, et al. Nosocomial infection, length of stay, and time-dependent bias. Infect Control Hosp Epidemiol 2009;30:273-276.
23. Beyersmann J, Wolkewitz M., Schumacher M.. The impact of timedependent bias in proportional hazards modelling. Stat Med 2008;27: 6439-6454.
24. Graves N, Weinhold D, Birrell F, et al. The effect ofhealthcare-acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol 2007;28:280-292. (Pubitemid 46480726)
25. Graves N, Weinhold D, Roberts JAR. Correcting for bias when estimating the cost of hospital acquired infection: an analysis of lower respiratory tract infections in non-surgical patients. Health Econ 2005; 14:755-761. (Pubitemid 40960229)
26. Cookson R. Willingness to pay methods in health care: a sceptical view. Health Economics 2003;12:891-894. (Pubitemid 37407334)
27. Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 2008;52:2119-2126.
28. Krupnick AJ. Valuing health outcomes: policy choices and technical issues. Vol 1. Washington, DC: Resources for the Future, 2004.
29. Birch S, Garni A. Cost effectiveness/utility analyses: do current decision rules lead us to where we want to be? J Health Econ 1992;11:279-296.
30. Coast J. Is economic evaluation in touch with society's health values? BMJ 2004;329:1233-1236.
31. Donaldson C, Currie G, Mitton C. Cost effectiveness analysis in health care: contradictions. BMJ 2002;325:891-894. (Pubitemid 35215266)
32. Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999;3(9). (Pubitemid 29289989)
33. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-227. (Pubitemid 39013284)
34. Haley RW, Schaberg D, Von Allmen S, et al. Estimating the extra charges and prolongation of hospitalization due to nosocomial infections: a comparison of methods. J Infect Dis 1980;141:248-257. (Pubitemid 10100305)
35. Scott RD, Soloman SL, McGowan JE. Applying economic principles to health care. Emerg Infect Dis 2001;7:282-285. (Pubitemid 32374345)
36. Venuti EK. The going-concern assumption revisited: assessing a company's future viability. CPA J 2004;74:40-43.
37. Roberts RR, Frutos PW, Ciavarella GC, et al. Distribution of fixed vs variable costs of hospital care. JAMA 1999;281:644-649. (Pubitemid 29098066)
38. Plowman RP, Graves N, Griffin MAS, et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. J Hosp Infect 2001;47:198-209. (Pubitemid 32631848)
39. Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother 2003;51:ii37-ii44.
40. Nathwani D. Health economic issues in the treatment ofdrug-resistant serious gram-positive infections. J Infect 2009;59(suppl 1):S40-S50.
41. Plowman RP, Graves N, Griffin M, et al. The socioeconomic burden of hospital acquired infection. London, UK: Public Health Laboratory Service, 1999.
42. Newhouse JP. The application of economics to problems of public health and the delivery of medical services. In: Holland W, Detels R, Knox EG. Textbook of public health. Oxford, UK: Oxford University Press, 1985.
43. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003;138:644-650. (Pubitemid 38124656)
44. Wolkewitz M, Vonberg R-P, Grundmann H, et al. Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models. Critical Care 2008; 12:R44. (Pubitemid 351611908)
45. Beyersmann J. A random time interval approach for analysing the impact of a possible intermediate event on a terminal event. Biom J 2007;49:742-749.
46. Beyersmann J, Gastmeier P, Grundmann H, et al. Use of multistate models to assess prolongation of intensive care unit stay due to nosocomial infection. Infect Control Hosp Epidemiol 2006;27:493-499. (Pubitemid 43835532)
47. Makuch RW. Adjusted survival curve estimation using covariates. J Chronic Dis 1982;35:437-443.
48. Haley RW Incidence and nature of endemic and epidemic nosocomial infections. In: Bennent JV, Brachman P. Hospital infections. Boston, MA: Little, Brown & Co, 1985.
49. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs and attributable mortality. JAMA 1994;271:1598-1601. (Pubitemid 24987508)
50. Piatt R. Mortality associated with nosocomial urinary tract infection. N Engl J Med 1982;307:637-642. (Pubitemid 12049911)
51. Frazier A, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-1961. (Pubitemid 30778489)
52. Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a modelling study. PLoS Med 2009;6: e1000110.
53. Mobley LR, Hoerger TJ, Wittenborn JS, et al. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Deds Making 2006;26:194-206.
54. Organisation for Economic Co-operation and Development (OECD). OECD health data 2007. http://www.oecd.org/document/30/0,3343,en-2649-34631-12968734- l-l-l-37407,00.html. Accessed 13 June 2009.